1. Academic Validation
  2. Myocardial mitochondrial antiviral signaling protein promotes heart Ischemia-reperfusion injury via RIG-I signaling in mice

Myocardial mitochondrial antiviral signaling protein promotes heart Ischemia-reperfusion injury via RIG-I signaling in mice

  • Nat Commun. 2025 Jun 2;16(1):5101. doi: 10.1038/s41467-025-60123-7.
Zhenyu Kang # 1 Mengling Yang # 1 Yue Liu # 2 Yang Gui 1 Yalan Dong 1 Haifeng Zhou 1 Zili Zhang 1 Mingyue Li 3 Heng Fan 1 Zheng Li 1 Junjie Lu 4 Junyi Li 1 Rui Zhu 1 Chengyu Yin 1 Boyi Liu 5 Feng Jiang 6 Kun Huang 7 Alexey Sarapultsev 8 Fangfei Li 9 Ge Zhang 10 Ling Zhao 11 Yanyi Wang 12 Yunjia Ning 12 13 Xiang Cheng 14 15 Sarajo K Mohanta 16 17 18 Changjun Yin 16 18 19 20 Shanshan Luo 21 Andreas J R Habenicht 22 23 24 25 Desheng Hu 26 27 28
Affiliations

Affiliations

  • 1 Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • 2 Cardiovascular Disease Center, Xiyuan Hospital of China academy of Chinese Medical Sciences, Beijing, China.
  • 3 Department of Gastroenterology, Zhongda Hospital, Southeast University, Nanjing, China.
  • 4 Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Hubei Province, Xiangyang, China.
  • 5 Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Zhejiang Chinese Medical University, Hangzhou, 310000, China.
  • 6 College of International Education, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • 7 School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • 8 Russian-Chinese Education and Research Center of System Pathology, South Ural State University, Chelyabinsk, Russia.
  • 9 Shum Yiu Foon Sum Bik Chuen Memorial Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
  • 10 Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
  • 11 State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, China.
  • 12 State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  • 13 Hubei Jiangxia Laboratory, Wuhan, China.
  • 14 Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • 15 Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • 16 Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.
  • 17 German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.
  • 18 Easemedcontrol R & D; Schraudolphstraße 5, Munich, Germany.
  • 19 Division of Vascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • 20 Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • 21 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. shsh689@126.com.
  • 22 Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany. Andreas.Habenicht@njglyy.com.
  • 23 German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany. Andreas.Habenicht@njglyy.com.
  • 24 Easemedcontrol R & D; Schraudolphstraße 5, Munich, Germany. Andreas.Habenicht@njglyy.com.
  • 25 Department of Cardiology, the Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Gulou, Nanjing, Jiangsu, China. Andreas.Habenicht@njglyy.com.
  • 26 Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Desheng.Hu@hust.edu.cn.
  • 27 Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Desheng.Hu@hust.edu.cn.
  • 28 China-Russia Medical Research Center for Stress Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Desheng.Hu@hust.edu.cn.
  • # Contributed equally.
Abstract

Myocardial ischemia-reperfusion injury (MIRI) is a life-threatening complication of myocardial infarcts, with inner mitochondrial membrane protein dysfunction involved in MIRI-induced heart injury. The role of outer mitochondrial membrane protein mitochondrial Antiviral signaling protein (MAVS) is unknown. Here, we show that MAVS expression increases in infarcted myocardium of male wild-type mice. Global MAVS-knock-out or myocardial-specific MAVS knockdown protects male mice from acute and chronic MIRI. MIRI induces double-stranded RNA in affected myocardium, activating intracellular retinoic acid-inducible gene I (RIG-I) signaling, which leads to MAVS aggregation and subsequent non-canonical downstream signaling. MAVS aggregates recruit tumor necrosis factor-associated factor family 6 (TRAF6) and transforming growth factor-β-activated kinase 1 (TAK1), the activating mitogen-activated protein kinase (MAPK) pathway and Apoptosis. MAVS-knock-out reduces c-jun-NH2 terminal kinase (JNK) phosphorylation and Apoptosis. JNK inhibition protects against MIRI in wild-type male mice, whereas JNK agonist impairs protection in MAVS-knock-out male mice. MIRI activates RIG-I/MAVS pathway and subsequently triggers the TAK1/TRAF6 complex, leading to the activation of the MAPK/JNK signaling cascade. This sequential activation cascade may serve as a potential therapeutic target for MIRI.

Figures
Products
Inhibitors & Agonists
Other Products